Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

Partida para intensificació durant la 2a i 3a anualitat

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 60000
Reference: PI18/00947_INT_GENESCA
Duration: 02/03/2020 - 30/06/2023

Targeted biodegradable nanoparticles of simvastatin as new therapeutic tool for chronic liver disease

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 80598
Reference: CD19/00049
Duration: 01/01/2020 - 18/04/2022

BIODEGRADABLE NANOPARTICLES OF SIMVASTATIN AS NEW THERAPEUTIC TOOL FOR CHRONIC LIVER DISEASE (NANOSIM)

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 199952
Reference: ISCIII/EURONANOMED/2018/NANOSIM/DUP
Duration: 22/10/2018 - 22/10/2018

BIODEGRADABLE NANOPARTICLES OF SIMVASTATIN AS NEW THERAPEUTIC TOOL FOR CHRONIC LIVER DISEASE (NANOSIM)

IP: Joan Genescà Ferrer
Collaborators: Maria Nieves Martell Pérez-Alcalde, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 199946.45
Reference: AC18/00033
Duration: 01/01/2019 - 31/12/2022

Related news

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Sara Mas Assens

Sara Mas Assens

Tècnic/a Grau Superior
Technical Secretary
Internal Strategy Directorate
Read more
Lucas Regis Plácido

Lucas Regis Plácido

Postdoctoral researcher
Biomedical Research in Urology
Read more
Francesc Xavier Serra Marin

Francesc Xavier Serra Marin

Research assistant
Biomedical Research in Gynaecology
Read more
Joan Comenge Farré

Joan Comenge Farré

Postdoctoral researcher
Pharmacokinetic Nanoparticles
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.